blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

Latvia joins the Federated Register
Click here for more information on the Federated Register.

2025-04-16

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3398949

EP3398949 - USES OF COMPOUND IN PREPARATION OF DRUGS FOR TREATING BRAIN GLIOMA [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  10.12.2021
Database last updated on 05.05.2025
FormerThe patent has been granted
Status updated on  01.01.2021
FormerGrant of patent is intended
Status updated on  25.06.2020
FormerRequest for examination was made
Status updated on  10.06.2020
FormerGrant of patent is intended
Status updated on  04.06.2020
FormerRequest for examination was made
Status updated on  05.10.2018
FormerThe international publication has been made
Status updated on  07.07.2017
Most recent event   Tooltip13.09.2024Lapse of the patent in a contracting state
New state(s): MT		published on 16.10.2024  [2024/42]
Applicant(s)For all designated states
Beijing Pearl Biotechnology Limited Liability Company
Room 402, 4F, Building 103
Lize Zhongyuan
Chaoyang District
Beijing 100102 / CN
For all designated states
Beijing Neurosurgical Institute
No.6 Tiantan Xili
Dongcheng District
Beijing 100050 / CN
[2021/01]
Former [2018/45]For all designated states
Beijing Pearl Biotechnology Limited Liability Company
Room 1305 of Reward Building A
No.203 Section 2
Lize Zhongyuan
Chaoyang District
Beijing 100102 / CN
For all designated states
Beijing Neurosurgical Institute
No.6 Tiantan Xili
Dongcheng District
Beijing 100050 / CN
Inventor(s)01 / JIANG, Tao
No.6 Tiantan Xili
Dongcheng District
Beijing 100050 / CN
02 / LIU, Yanwei
No.6 Tiantan Xili
Dongcheng District
Beijing 100050 / CN
03 / HU, Huimin
No.6 Tiantan Xili
Dongcheng District
Beijing 100050 / CN
04 / SHI, Hepeng
c/o Beijing Pearl Biotechnology Limited
Liability Company
Room 402, 4F, Building 103
Lize Zhongyuan, Chaoyang District
Beijing 100102 / CN
05 / XUE, Weizhe
c/o Beijing Pearl Biotechnology Limited
Liability Company
Room 402, 4F, Building 103
Lize Zhongyuan, Chaoyang District
Beijing 100102 / CN
 [2020/52]
Former [2018/45]01 / JIANG, Tao
No.6 Tiantan Xili
Dongcheng District
Beijing 100050 / CN
02 / LIU, Yanwei
No.6 Tiantan Xili
Dongcheng District
Beijing 100050 / CN
03 / HU, Huimin
No.6 Tiantan Xili
Dongcheng District
Beijing 100050 / CN
04 / SHI, Hepeng
Room 1305 of Reward Building A
No.203 Section 2
Lize Zhongyuan
Chaoyang District
Beijing 100102 / CN
05 / XUE, Weizhe
Room 1305 of Reward Building A
No.203 Section 2
Lize Zhongyuan
Chaoyang District
Beijing 100102 / CN
Representative(s)Schiweck Weinzierl Koch Patentanwälte Partnerschaft mbB
Ganghoferstraße 68 B
80339 München / DE
[2018/45]
Application number, filing date16881038.021.12.2016
[2018/45]
WO2016CN111227
Priority number, dateCN2015112239131.12.2015         Original published format: CN201511022391
[2018/45]
Filing languageZH
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2017114249
Date:06.07.2017
Language:ZH
[2017/27]
Type: A1 Application with search report 
No.:EP3398949
Date:07.11.2018
Language:EN
[2018/45]
Type: B1 Patent specification 
No.:EP3398949
Date:03.02.2021
Language:EN
[2021/05]
Search report(s)International search report - published on:CN06.07.2017
(Supplementary) European search report - dispatched on:EP02.08.2019
ClassificationIPC:C07D487/04, C07D471/04, C07D513/04, A61K31/5025, A61K31/5377, A61K31/437, A61K31/519, A61K31/433, A61P35/00
[2019/36]
CPC:
A61K31/433 (EP); A61K31/5025 (EP,CN,KR,US); A61K31/437 (EP);
A61K31/519 (EP); A61K31/5377 (EP); A61P35/00 (KR,US);
C07D471/04 (EP,KR); C07D487/04 (EP,KR); C07D513/04 (EP,KR);
C07K14/71 (KR); C12N5/0693 (KR); C12N9/16 (KR);
C07K2319/00 (KR); C12Y301/03048 (KR) (-)
Former IPC [2018/45]C07D487/04, C07D471/04, C07D513/04, A61K31/5025, A61K31/5377, A61K31/437, A61K31/519, A61K31/433
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2018/45]
Extension statesBANot yet paid
MENot yet paid
Validation statesMANot yet paid
MDNot yet paid
TitleGerman:VERWENDUNG EINER VERBINDUNG IN DER HERSTELLUNG VON ARZNEIMITTELN ZUR BEHANDLUNG VON HIRNGLIOMEN[2018/45]
English:USES OF COMPOUND IN PREPARATION OF DRUGS FOR TREATING BRAIN GLIOMA[2018/45]
French:UTILISATIONS DE COMPOSÉ DANS LA PRÉPARATION DE MÉDICAMENTS POUR LE TRAITEMENT DU GLIOME CÉRÉBRAL[2018/45]
Entry into regional phase11.07.2018Translation filed 
24.07.2018National basic fee paid 
24.07.2018Search fee paid 
24.07.2018Designation fee(s) paid 
24.07.2018Examination fee paid 
Examination proceduredeletedDate on which the examining division has become responsible
24.07.2018Examination requested  [2018/45]
09.01.2020Amendment by applicant (claims and/or description)
22.07.2020Communication of intention to grant the patent
16.11.2020Receipt of the translation of the claim(s)
01.12.2020Fee for grant paid
01.12.2020Fee for publishing/printing paid
Opposition(s)04.11.2021No opposition filed within time limit [2022/02]
Fees paidRenewal fee
19.12.2018Renewal fee patent year 03
23.12.2019Renewal fee patent year 04
24.12.2020Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU21.12.2016
AL03.02.2021
AT03.02.2021
CY03.02.2021
CZ03.02.2021
DK03.02.2021
EE03.02.2021
FI03.02.2021
HR03.02.2021
LT03.02.2021
LV03.02.2021
MC03.02.2021
MK03.02.2021
MT03.02.2021
NL03.02.2021
PL03.02.2021
RO03.02.2021
RS03.02.2021
SE03.02.2021
SI03.02.2021
SK03.02.2021
SM03.02.2021
BG03.05.2021
NO03.05.2021
GR04.05.2021
IS03.06.2021
PT04.06.2021
[2024/42]
Former [2024/22]HU21.12.2016
AL03.02.2021
AT03.02.2021
CY03.02.2021
CZ03.02.2021
DK03.02.2021
EE03.02.2021
FI03.02.2021
HR03.02.2021
LT03.02.2021
LV03.02.2021
MC03.02.2021
MK03.02.2021
NL03.02.2021
PL03.02.2021
RO03.02.2021
RS03.02.2021
SE03.02.2021
SI03.02.2021
SK03.02.2021
SM03.02.2021
BG03.05.2021
NO03.05.2021
GR04.05.2021
IS03.06.2021
PT04.06.2021
Former [2023/33]HU21.12.2016
AL03.02.2021
AT03.02.2021
CY03.02.2021
CZ03.02.2021
DK03.02.2021
EE03.02.2021
FI03.02.2021
HR03.02.2021
LT03.02.2021
LV03.02.2021
MC03.02.2021
NL03.02.2021
PL03.02.2021
RO03.02.2021
RS03.02.2021
SE03.02.2021
SI03.02.2021
SK03.02.2021
SM03.02.2021
BG03.05.2021
NO03.05.2021
GR04.05.2021
IS03.06.2021
PT04.06.2021
Former [2023/30]AL03.02.2021
AT03.02.2021
CY03.02.2021
CZ03.02.2021
DK03.02.2021
EE03.02.2021
FI03.02.2021
HR03.02.2021
LT03.02.2021
LV03.02.2021
MC03.02.2021
NL03.02.2021
PL03.02.2021
RO03.02.2021
RS03.02.2021
SE03.02.2021
SI03.02.2021
SK03.02.2021
SM03.02.2021
BG03.05.2021
NO03.05.2021
GR04.05.2021
IS03.06.2021
PT04.06.2021
Former [2022/33]AL03.02.2021
AT03.02.2021
CZ03.02.2021
DK03.02.2021
EE03.02.2021
FI03.02.2021
HR03.02.2021
LT03.02.2021
LV03.02.2021
MC03.02.2021
NL03.02.2021
PL03.02.2021
RO03.02.2021
RS03.02.2021
SE03.02.2021
SI03.02.2021
SK03.02.2021
SM03.02.2021
BG03.05.2021
NO03.05.2021
GR04.05.2021
IS03.06.2021
PT04.06.2021
Former [2022/23]AL03.02.2021
AT03.02.2021
CZ03.02.2021
DK03.02.2021
EE03.02.2021
FI03.02.2021
HR03.02.2021
LT03.02.2021
LV03.02.2021
NL03.02.2021
PL03.02.2021
RO03.02.2021
RS03.02.2021
SE03.02.2021
SI03.02.2021
SK03.02.2021
SM03.02.2021
BG03.05.2021
NO03.05.2021
GR04.05.2021
IS03.06.2021
PT04.06.2021
Former [2022/13]AL03.02.2021
AT03.02.2021
CZ03.02.2021
DK03.02.2021
EE03.02.2021
FI03.02.2021
HR03.02.2021
LT03.02.2021
LV03.02.2021
NL03.02.2021
PL03.02.2021
RO03.02.2021
RS03.02.2021
SE03.02.2021
SI03.02.2021
SK03.02.2021
SM03.02.2021
BG03.05.2021
NO03.05.2021
GR04.05.2021
PT04.06.2021
Former [2022/10]AL03.02.2021
AT03.02.2021
CZ03.02.2021
DK03.02.2021
EE03.02.2021
FI03.02.2021
HR03.02.2021
LT03.02.2021
LV03.02.2021
NL03.02.2021
PL03.02.2021
RO03.02.2021
RS03.02.2021
SE03.02.2021
SK03.02.2021
SM03.02.2021
BG03.05.2021
NO03.05.2021
GR04.05.2021
PT04.06.2021
Former [2022/07]AL03.02.2021
AT03.02.2021
CZ03.02.2021
DK03.02.2021
EE03.02.2021
FI03.02.2021
HR03.02.2021
LT03.02.2021
LV03.02.2021
NL03.02.2021
PL03.02.2021
RO03.02.2021
RS03.02.2021
SE03.02.2021
SK03.02.2021
SM03.02.2021
BG03.05.2021
NO03.05.2021
GR04.05.2021
IS03.06.2021
PT04.06.2021
Former [2021/50]AT03.02.2021
CZ03.02.2021
DK03.02.2021
EE03.02.2021
FI03.02.2021
HR03.02.2021
LT03.02.2021
LV03.02.2021
NL03.02.2021
PL03.02.2021
RO03.02.2021
RS03.02.2021
SE03.02.2021
SK03.02.2021
SM03.02.2021
BG03.05.2021
NO03.05.2021
GR04.05.2021
IS03.06.2021
PT04.06.2021
Former [2021/49]AT03.02.2021
CZ03.02.2021
DK03.02.2021
EE03.02.2021
FI03.02.2021
HR03.02.2021
LT03.02.2021
LV03.02.2021
NL03.02.2021
PL03.02.2021
RS03.02.2021
SE03.02.2021
SM03.02.2021
BG03.05.2021
NO03.05.2021
GR04.05.2021
IS03.06.2021
PT04.06.2021
Former [2021/48]AT03.02.2021
CZ03.02.2021
EE03.02.2021
FI03.02.2021
HR03.02.2021
LT03.02.2021
LV03.02.2021
NL03.02.2021
PL03.02.2021
RS03.02.2021
SE03.02.2021
SM03.02.2021
BG03.05.2021
NO03.05.2021
GR04.05.2021
IS03.06.2021
PT04.06.2021
Former [2021/46]AT03.02.2021
FI03.02.2021
HR03.02.2021
LT03.02.2021
LV03.02.2021
NL03.02.2021
PL03.02.2021
RS03.02.2021
SE03.02.2021
SM03.02.2021
BG03.05.2021
NO03.05.2021
GR04.05.2021
IS03.06.2021
PT04.06.2021
Former [2021/42]AT03.02.2021
FI03.02.2021
HR03.02.2021
LT03.02.2021
LV03.02.2021
NL03.02.2021
PL03.02.2021
RS03.02.2021
SE03.02.2021
BG03.05.2021
NO03.05.2021
GR04.05.2021
IS03.06.2021
PT04.06.2021
Former [2021/39]AT03.02.2021
FI03.02.2021
HR03.02.2021
LT03.02.2021
LV03.02.2021
NL03.02.2021
PL03.02.2021
RS03.02.2021
SE03.02.2021
BG03.05.2021
NO03.05.2021
GR04.05.2021
PT04.06.2021
Former [2021/38]AT03.02.2021
FI03.02.2021
HR03.02.2021
LT03.02.2021
LV03.02.2021
NL03.02.2021
RS03.02.2021
SE03.02.2021
BG03.05.2021
NO03.05.2021
GR04.05.2021
PT04.06.2021
Former [2021/37]AT03.02.2021
FI03.02.2021
HR03.02.2021
LT03.02.2021
LV03.02.2021
RS03.02.2021
BG03.05.2021
NO03.05.2021
GR04.05.2021
PT04.06.2021
Former [2021/36]FI03.02.2021
HR03.02.2021
LT03.02.2021
BG03.05.2021
NO03.05.2021
GR04.05.2021
PT04.06.2021
Former [2021/35]FI03.02.2021
HR03.02.2021
LT03.02.2021
NO03.05.2021
PT04.06.2021
Former [2021/33]FI03.02.2021
LT03.02.2021
NO03.05.2021
PT04.06.2021
Documents cited:Search[A]US2012028984  (WU ZHIPEI [US]) [A] 1-9 * abstract * * paragraphs [0054] - [0059] - [0079] * * claim - *;
 [A]WO2014000713  (ZHEJIANG BETA PHARMA INC [CN], et al) [A] 1-9 * abstract * * page 57, lines 2-4 * * pages 58-59 * * claim - *;
 [A]WO2014032498  (CROWN BIOSCIENCE INC TAICANG [CN]) [A] 1-9 * abstract * * page 30; compound 44 * * page 33; table 3; compound 44 * * claim - *;
 [A]US2015037280  (XI NING [US], et al) [A] 1-9 * abstract * * paragraphs [0009] , [0010] , [0041] , [0530] - [0533] - [0536] - [0537] * * claim - *;
 [A]  - HUI-MIN CHEN ET AL, "Enhanced expression and phosphorylation of the MET oncoprotein by glioma-specific PTPRZ1-MET fusions", FEBS LETTERS., NL, (20150429), vol. 589, no. 13, doi:10.1016/j.febslet.2015.04.032, ISSN 0014-5793, pages 1437 - 1443, XP055507079 [A] 1-9 * the whole document *

DOI:   http://dx.doi.org/10.1016/j.febslet.2015.04.032
 [A]  - ZHAO-SHI BAO ET AL, "RNA-seq of 272 gliomas revealed a novel, recurrent PTPRZ1-MET fusion transcript in secondary glioblastomas", GENOME RESEARCH, (20140818), vol. 24, no. 11, doi:10.1101/gr.165126.113, ISSN 1088-9051, pages 1765 - 1773, XP055202258 [A] 1-9 * the whole document *

DOI:   http://dx.doi.org/10.1101/gr.165126.113
 [T]  - HU HUIMIN ET AL, "Mutational Landscape of Secondary Glioblastoma Guides MET-Targeted Trial in Brain Tumor", CELL, ELSEVIER, AMSTERDAM, NL, (20181018), vol. 175, no. 6, doi:10.1016/J.CELL.2018.09.038, ISSN 0092-8674, page 1665, XP085544086 [T] 1-9 * the whole document *

DOI:   http://dx.doi.org/10.1016/j.cell.2018.09.038
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.